The safety of long-term use of inhaled corticosteroids in patients with asthma : A systematic review and meta-analysis
Copyright © 2022 Elsevier Inc. All rights reserved.
| Veröffentlicht in: | Clinical immunology (Orlando, Fla.). - 1999. - 236(2022) vom: 15. März, Seite 108960 |
|---|---|
| 1. Verfasser: | |
| Weitere Verfasser: | , , |
| Format: | Online-Aufsatz |
| Sprache: | English |
| Veröffentlicht: |
2022
|
| Zugriff auf das übergeordnete Werk: | Clinical immunology (Orlando, Fla.) |
| Schlagworte: | Journal Article Meta-Analysis Review Systematic Review Adverse events Asthma Inhaled corticosteroids meta-analysis Adrenal Cortex Hormones Anti-Asthmatic Agents |
| Zusammenfassung: | Copyright © 2022 Elsevier Inc. All rights reserved. PURPOSE: This systematic review and meta-analysis was performed to determine the safety of long-term use of ICS in patients with asthma METHODS: A systematic search was made of PubMed, Embase, Web of Science, Cochrane Library, and clinicaltrials.gov, without language restrictions. Randomized controlled trials (RCTs) on treatment of asthma with ICS, compared with non-ICS treatment (placebo or other active drugs), were reviewed RESULTS: Eighty-six RCTs (enrolling 51,538 participants) met the inclusion criteria. Oral or oropharyngeal candidiasis (RR 2.58, 95% CI 2.00 to 3.33), and dysphonia/hoarseness (RR 1.56, 95% CI 1.31 to 1.85) were less frequent in the control group. There was no statistically significant difference in the risk of upper respiratory tract infection, lower respiratory tract infection, influenza, decline in bone mineral density, and fractures between the two groups CONCLUSION: In addition to the mild local adverse events, the long-term use of ICS was safe in patients with asthma |
|---|---|
| Beschreibung: | Date Completed 06.05.2022 Date Revised 06.05.2022 published: Print-Electronic Citation Status MEDLINE |
| ISSN: | 1521-7035 |
| DOI: | 10.1016/j.clim.2022.108960 |